WARRENDALE, Pa., May 22 MEDRAD, INC., announced today thatits XDS(TM) Extravasation Detector has received a 2008 Medical DesignExcellence Award(R) (MDEA). The XDS employs a technology that aids in thedetection of leaking intravenous contrast media from the injection site intosurrounding tissue during computed tomography (CT) diagnostic studies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )
"This prestigious award recognizes our XDS Extravasation Detectortechnology, the investment of many resources for research and development, andthe inherent risk of developing medical devices; the MDEA validates that theinvestment and risk were worth it," said Cliff Kress, senior vice president,MEDRAD CT Business Unit. "We are proud that we have succeeded in developingan extravasation technology that continues MEDRAD's long-standing commitmentto patient safety."
The MDEA competition, presented by Canon Communications and sponsored byMedical Device & Diagnostic Industry Magazine, recognizes medical productexcellence in design and engineering features, innovative use of materials,user-related functions that improve healthcare delivery, features that benefitpatients, and the ability of the development team to overcome challenges. Animpartial, multi-disciplinary panel of jurors with expertise in biomedicalengineering, human factors, industrial design, medicine, and diagnosticsreviewed the entries and selected the winners.
MEDRAD and development partner, Battelle Medical Device Solutions, willaccept the award at a ceremony June 4 at the Medical Design & Manufacturing(MD&M) East 2008 Conference and Exposition in New York City.
More information on the XDS Extravasation Detector is available on theMEDRAD Web site at www.medrad.com/products/ct/xds-extravasation-detector.html.
MEDRAD INC. is a worldwide leading provider of medical devices andservices that enable and enhance imaging procedures of the human body. Usedin diagnostic imaging, MEDRAD's product offerings include a comprehensive lineof vascular injection systems, magnetic resonance (MR) surface coils andpatient care products, and equipment services. Total 2007 revenues were $525million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National QualityAward, the top honor a U.S. company can receive for quality and businessexcellence. The company's world headquarters is near Pittsburgh,Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. Morecompany information is available at http://www.medrad.com.
The Bayer Group is a global enterprise with core competencies in thefields of healthcare, nutrition and high-tech materials. Bayer HealthCare, asubsidiary of Bayer AG, is one of the world's leading, innovative companies inthe healthcare and medical products industry and is based in Leverkusen,Germany. The company combines the global activities of the Animal Health,Consumer Care, Diabetes Care and Pharmaceuticals divisions. Thepharmaceuticals business operates under the name Bayer Schering Pharma AG.Bayer HealthCare's aim is to discover and manufacture products that willimprove human and animal health worldwide. Find more information athttp://www.bayerhealthcare.com.
Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reportedfinancial results nor other historical information are forward-lookingstatements, including but not limited to, statements that are predictions ofor indicate future events, trends, plans or objectives. Undue reliance shouldnot be placed on such statements because, by their nature, they are subject toknown and unknown risks and uncertainties and can be affected by other factorsthat could cause actual results and MEDRAD's plans and objectives to differmaterially from those expressed or implied in the forward-looking statements.MED